Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

Clinical trial NCT06908096 · RECRUITING

Trial details

NCT number: NCT06908096
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

EBV Epstein-Barr Virus Infection Infectious Mononucleosis Mono

Start date: 2025-05-29
Primary completion: 2027-10-01
Enrollment: 750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.